BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

Somatic mutations and the hierarchy of hematopoiesis

(2010) Arne Traulsen et al.   BIOESSAYS

Three decades of transplantation for chronic myeloid leukemia: what have we learned?

(2010) J. Pavlu et al.   BLOOD

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response definitions and European Leukemianet Management recommendations

(2009) Michele Baccarani et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

(2009) M. C. Muller et al.   BLOOD

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

(2009) E. Jabbour et al.   BLOOD

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

(2009) S. Soverini et al.   BLOOD

Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

(2009) G. Rosti et al.   BLOOD

Does a rise in theBCR-ABL1transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?

(2009) David Marin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

(2009) Yesid Alvarado et al.   CANCER

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

(2009) Hagop M. Kantarjian et al.   CANCER

Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response

(2009) F. Palandri et al.   CLINICAL CANCER RESEARCH

High rates of durable response are achieved with imatinib after treatment with interferon   plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

(2009) F. Guilhot et al.   HAEMATOLOGICA

A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib

(2009) T. Ernst et al.   HAEMATOLOGICA

Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response

(2009) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

(2009) Jane F. Apperley et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

(2009) Timothy Hughes et al.   JOURNAL OF CLINICAL ONCOLOGY

Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase

(2009) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia

(2009) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Imatinib dose escalation for chronic phase–chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy

(2009) D Rea et al.   LEUKEMIA

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

(2008) E. Jabbour et al.   BLOOD

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

(2008) D. Marin et al.   BLOOD

Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations

(2008) Tai-Sung Lee et al.   CANCER

ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

(2008) T. Ernst et al.   HAEMATOLOGICA

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

(2008) T. Ernst et al.   HAEMATOLOGICA

Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression

(2008) Jamshid S. Khorashad et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants

(2008) Sara Redaelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

(2008) A Hochhaus et al.   LEUKEMIA

Long-Term Outcome of Complete Cytogenetic Responders After Imatinib 400 mg in Late Chronic Phase, Philadelphia-Positive Chronic Myeloid Leukemia: The GIMEMA Working Party on CML

(2007) Francesca Palandri et al.   JOURNAL OF CLINICAL ONCOLOGY